Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2007 Dec;117(12):3623-32.

Nonviral delivery of synthetic siRNAs in vivo.

Author information

1
SA Pharma, Sutton Coldfield, West Midlands, United Kingdom. SA_Pharma@hotmail.co.uk

Abstract

Sequence-specific gene silencing using small interfering RNA (siRNA) is a Nobel prize-winning technology that is now being evaluated in clinical trials as a potentially novel therapeutic strategy. This article provides an overview of the major pharmaceutical challenges facing siRNA therapeutics, focusing on the delivery strategies for synthetic siRNA duplexes in vivo, as this remains one of the most important issues to be resolved. This article also highlights the importance of understanding the genocompatibility/toxicogenomics of siRNA delivery reagents in terms of their impact on gene-silencing activity and specificity. Collectively, this information is essential for the selection of optimally acting siRNA delivery system combinations for the many proposed applications of RNA interference.

PMID:
18060020
PMCID:
PMC2096447
DOI:
10.1172/JCI33494
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Society for Clinical Investigation Icon for PubMed Central
    Loading ...
    Support Center